SEC Info - Abvc Biopharma, Inc. - ‘8-K’ for 9/4/22

SEC Info℠

Home

Help

Please Sign In

Abvc Biopharma, Inc. – ‘8-K’ for 9/4/22

On: Friday, 9/9/22, at 4:30pm ET · For: 9/4/22 · Accession #: 1213900-22-55075 · File #: 1-40700

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/09/22  Abvc Biopharma, Inc.              8-K:5       9/04/22   10:181K                                   EdgarAgents LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 5: R1          Cover                                               HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- ea165554-8k_abvcbio_htm             XML     14K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- abvc-20220904_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- abvc-20220904_pre              XML     63K 
 2: EX-101.SCH  XBRL Schema -- abvc-20220904                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
10: ZIP         XBRL Zipped Folder -- 0001213900-22-055075-xbrl      Zip     15K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0001173313 i false 0001173313 2022-09-04 2022-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i September 4, 2022

i ABVC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

i Nevada		i 333-91436		i 26-0014658
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i 44370 Old Warm Springs Blvd.

i Fremont, i CA

i 94538

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: i (510) i 668-0881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of each exchange on which registered
i Common Stock, par value $0.001 per share		i ABVC		The i Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the board meeting held on September 4, 2022, the Board has determined that it is in the best interests of ABVC BIOPHARMA, INC. (the “Company”) to reappoint Leeds Chow, age 34, the Company’s Controller, as Chief Financial Officer and Principal Accounting Officer.

Leeds Chow, age 34, has served as a Controller of the Company since March 2021. Mr. Chow has over 12 years of experience in Audit and Financing Industry. He has served as the finance manager in a family office, in charge of managing investment portfolios, handling financial and operating aspects. He has also worked in a local investment company in Hong Kong, serving as a financial advisor during the Hong Kong Initial Public Offering process, as well as preparing opinion letters as an independent financial advisor for transactions for Hong Kong listed companies. Mr. Chow graduated in University of California, Santa Barbara, with a Bachelor of Arts degree, majoring in Business Economics with Accounting Emphasis.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABVC BioPharma, Inc.

September 9, 2022	By:	/s/ *Howard Doong*
		Howard Doong
		Chief Executive Officer

Dates Referenced Herein

This ‘8-K’ Filing	Date	Other Filings

Filed on:	9/9/22	None on these Dates
For Period end:	9/4/22
		List all Filings

↑Top

Filing Submission 0001213900-22-055075 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)